

Norelgestromin, ethinylestradiol patch (Evra[®])

(No. 48/03)

Janssen-Cilag
Summary of Recommendation

8 September 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Recommended for restricted use within NHS Scotland.

RECOMMENDATION

Norelgestromin / ethinylestradiol (Evra[®]) patches have efficacy and an adverse-effect profile similar to combined oral contraceptives (COCs). There is some evidence of improved overall compliance with this preparation compared with COCs. It is more expensive than these oral contraceptives. Nevertheless, it is concluded that this preparation may be of benefit in the group of women who have demonstrated-, or are deemed to be at-, substantial risk of poor compliance with COCs. Use of EVRA should be restricted to this group of people.

Professor David H Lawson
Chairman